Skip to content
Search

Latest Stories

Australian players likely to pull out of The Hundred

Australian players likely to pull out of The Hundred

THERE are chances of Australian players pulling out of The Hundred because of border restrictions in Australia due to Covid-19.

Australia batter Rachel Haynes has withdrawn from her contract with Oval Invincibles and most likely in the coming weeks other Australian players are expected to pull out.


With a quarantine period of two weeks in place and low remuneration for women players, with the maximum pay being £15,000 - many players from Australia are still considering about the decision to travel.

According to a report in The Times, players like Ellyse Perry, Meg Lanning and Alyssa Healy who are part of the tournament are considering their options. Their male counterparts may also have to withdraw looking at international duties to be affected by quarantine.

Australia's men are due to play three T20s and three ODIs against the West Indies in the Caribbean in late June and early July. With a white-ball series immediately scheduled next in Bangladesh, that would leave only a week for players to get to the UK before the start of the Hundred on July 22.

Bangladesh being on UK's red list, which means the Australian players and support staff would have to undergo a mandatory 10-day quarantine.

There are nine Australian men to have signed for The Hundred, including David Warner and Glenn Maxwell having signed for Southern Brave and London Spirit respectively. As The Times report suggest, both the players' participation looks doubtful.

Each team in The Hundred are allowed to have three overseas players in a squad of 15, and replacements could be found from the touring teams of Sri Lanka and Pakistan who will be in the UK for limited-overs series in June and July.

If overseas players withdraw then it would be a big blow to the popularity of the tournament, which the ECB is hosting with an expenditure of £40 million a year.

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less